Inactief instrument

Koers Transition Therapeutics Inc

Aandelen

Duur

Periode

Stijl

Transition Therapeutics : Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.	26-08-16
Transition Therapeutics : Receives Notification From NASDAQ	03-06-16
Transition Therapeutics : Announces Third Quarter Fiscal 2016 Financial Results	11-05-16
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST	09-05-16
Transition Therapeutics : Provides Update on Type 2 Diabetes Drug Candidate TT401	18-04-16

Managers	Titel	Leeftijd	Van
Antonio F. Cruz CEO	Chief Executive Officer	71	06-07-98

Besturend	Titel	Leeftijd	Van
Antonio F. Cruz CEO	Chief Executive Officer	71	06-07-98

Sector

	Vaira. 1 jan.	Kapi.
CSL LIMITED	-4,66%	86,13 mld.
SAMSUNG BIOLOGICS CO.,LTD.	+1,32%	39,82 mld.
BIOGEN INC.	-19,27%	30,42 mld.
UCB	+57,86%	25,23 mld.
INCYTE CORPORATION	-17,69%	11,6 mld.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43,00%	11,51 mld.
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9,14%	11,95 mld.
SWEDISH ORPHAN BIOVITRUM AB	+5,24%	8,71 mld.
INNOVENT BIOLOGICS, INC.	-8,42%	8,12 mld.